The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy
Clinical Radiology Nov 01, 2019
Nakajo M, Kitajima K, Kaida H, et al. - Researchers investigated the utility of Positron Emission Tomography Response Criteria in Solid Tumours (PERCIST) in predicting tumour response as well as prognosis in patients (n = 60) with oesophageal cancer treated by neoadjuvant chemoradiotherapy (NACRT) followed by surgery in this multicentre retrospective analysis. They found a significant correlation between pathological response and PERCIST. In univariate analysis, the significance of the pathological stage and PERCIST for progression-free survival (PFS) and also for overall survival (OS) was revealed. Also, univariate analysis showed the importance of pathological lymph node staging for OS. PERCIST continued to be significant as well as independent for PFS and OS at multivariate analysis. Overall, the possible utility of PERCIST for tumour response and prognosis prediction in NACRT-treated oesophageal cancer cases was suggested.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries